Akrivis Technologies, LLC is committed to the early detection, diagnosis and treatment of serious and life-threatening diseases based on its patented Z-TECTTM technology platform. Z-TECTTM is a new nanotechnology-based technique for detecting unusually low levels of protein and molecular targets. Unlike traditional methods, which are not readily adaptable to multiple assay formats and require special detection equipment, Akrivisâ Z-TECTTM technology platform amplifies true signal at the source. This comprehensive approach allows unparalleled access to the entire spectrum of immunoassays and detection platforms. With ultra low limits-of-detection several thousand fold lower than currently achievable, Z-TECTTM makes it possible to vastly improve the early detection of cancer biomarkers in vitro. Z-TECTTM is also capable of imaging millimeter-size micro-lesions in animal models and makes cancer detection in vivo now possible at much lower levels of growth